Document:

EX-10.14

 Exhibit 10.14 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT NONEXCLUSIVE – SUBLICENSABLE 

and 
 BIOLOGICAL MATERIALS
LICENSE-NON-EXCLUSIVE 
 This Agreement is based
on the model Patent License Non-Exclusive Sublicensable Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National
Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of
Health and Human Services (“HHS”). 
 This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

National Institute of Allergy and Infectious Diseases 

an Institute or Center (hereinafter referred to as the “NIAID”) of the 

NIH 
 and 

Icosavax, Inc., 
 hereinafter
referred to as the “Licensee”, 
 having offices at 1 Union Square, 600 University Street, Suite 2525, Seattle, Washington
98101, 
 created and operating under the laws of Delaware. 

Tax ID No.:            [***] 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 1
 of 36     [Final]     [Icosavax, Inc.] 

 For the NIAID’s internal use only: 

License Number: 
 License
Application Number: [***] 
 Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

 

	 	●	 	 [***] 

Licensee: Icosavax, Inc. 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A 

Additional Remarks: 
 Public
Benefit(s): Development of nanoparticle-based respiratory syncytial virus (“RSV”) vaccines 
 This Patent License Agreement, hereinafter
referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties),
Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), Appendix G (Royalty Payment Options, and Appendix H (Shipping Information). 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 2
 of 36     [Final]     [Icosavax, Inc.] 

 The NIAID and the Licensee agree as follows: 

 

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the NIAID investigators made inventions
that may have commercial applicability. 

  

	 	1.2	 By assignment of rights from the NIAID employees and other inventors, HHS, on behalf of the
Government, solely owns the Licensed Patent Rights listed in Appendix A (I and II) and jointly owns Licensed Patent Rights listed in Appendix A (III) claimed in any United States or foreign patent applications or patents
corresponding to the assigned inventions. HHS also owns any tangible embodiments of the inventions claimed therein actually reduced to practice by the NIAID. 

 

	 	1.3	 The Secretary of HHS has delegated to the NIAID the authority to enter into this Agreement
for the licensing of rights to these inventions under 35 U.S.C. §§200-212, the Federal Technology Transfer Act of 1986, 15 U.S.C. §3710(a), and the regulations governing the licensing of Government-owned inventions, 37 CFR Part 404. 

  

	 	1.4	 The NIAID desires to transfer these inventions to the private sector through commercialization licenses
to facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Affiliate(s)” of Licensee means a corporation or other business entity, which directly
or indirectly is controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” means ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the
corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.2	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 3
 of 36     [Final]     [Icosavax, Inc.] 

	 	2.3	 “BLA” means a Biologics License Application or similar application or submission for marketing
approval filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

  

	 	2.4	 “Clinical Trial” means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical
Trial and/or Phase IV Clinical Trial conducted in the United States or outside of the United States. 

  

	 	2.5	 “Commercial Development Plan” means the written commercialization plan attached as Appendix E.

  

	 	2.6	 “First Commercial Sale” means (a) with respect to a Licensed Product, the initial
transfer by or on behalf of the Licensee or any of its Affiliates or sublicensees of such Licensed Product to a third party (other than a sublicensee), in exchange for cash or some equivalent to which value can be
assigned for the purpose of determining Net Sales, for end use of such Licensed Product in a regulatory jurisdiction after approval by a Regulatory Authority has been granted for such Licensed Product in such regulatory
jurisdiction or (b) the initial practice of a Licensed Process by or on behalf of the Licensee or any of its Affiliates or sublicensees for a third party (other than a sublicensee) in exchange for cash or some
equivalent to which value can be assigned for the purpose of determining Net Sales. 

  

	 	2.7	 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereto.

  

	 	2.8	 “Government” means the Government of the United States of America. 

 

	 	2.9	 “IND” means an Investigational New Drug application, Clinical Study Application, Clinical
Trial Exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

 

	 	2.10	 “Least Developed Countries” means those countries listed in Appendix B, subsection IV.

  

	 	2.11	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 4
 of 36     [Final]     [Icosavax, Inc.] 

	 	2.12	 “Licensed Additional Documentation” means information and materials, owned, controlled or
generated by the NIAID inventors’ laboratory, including, but not limited to, [***] and which during the term of this Agreement (i) are in the possession or control of NIAID, and (ii) are necessary or useful to
Licensee in the Licensed Fields of Use, including without limitation, in connection with the research, development, manufacture, use or sale of Licensed Products in the Licensed Territory. 

 

	 	2.13	 “Licensed Materials” means tangible biological materials, identified in Appendix B, including
progeny, subclones, expressed antibody proteins, unmodified derivatives, fractions or components isolated therefrom, whether or not within the scope of the claims of the Licensed Patent Rights. 

 

	 	2.14	 “Licensed Patent Rights” means: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.14(a): 

  

	 	(i)	 continuations-in-part of
2.14(a); 

  

	 	(ii)	 all divisions and continuations of these
continuations-in-part; 

  

	 	(iii)	 all patents issuing from these
continuations-in-part, divisions, and continuations; 

  

	 	(iv)	 priority patent application(s) of 2.14(a); and 

 

	 	(v)	 any reissues, reexaminations, and extensions of all these patents; 

 

	 	(c)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.14(a): all counterpart foreign and U.S. patent applications and patents to 2.14(a) and 2.14(b), including those listed in Appendix A; and 

  

	 	(d)	 Licensed Patent Rights shall not include 2.14(b) or 2.14(c) to the extent that they contain one
or more claims directed to new matter which is not the subject matter disclosed in 2.14(a). 

  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 5
 of 36     [Final]     [Icosavax, Inc.] 

	 	2.15	 “Licensed Processes” means processes, which in the course of being practiced, would be within
the scope of one or more claims of the Licensed Patent Rights in the country in which such processes are practiced that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of
competent jurisdiction. 

  

	 	2.16	 “Licensed Products” means tangible materials, which in the course of manufacture, use, sale,
or importation, would be within the scope of one or more claims of the Licensed Patent Rights in the country of such manufacture, use, sale, or importation, as applicable that have not been held unpatentable, invalid or unenforceable by an
unappealed or unappealable judgment of a court of competent jurisdiction. 

  

	 	2.17	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.18	 “Major Market” means any one of the following countries: United States, Japan, the United
Kingdom, France, Germany, Italy or Spain. 

  

	 	2.19	 “Net Sales” means with respect to any Licensed Product or Licensed Process, the
total gross receipts for sales of such Licensed Product(s) or practice of Licensed Process(es) by or on behalf of the Licensee or of its Affiliates or sublicensees to third parties, and from leasing, renting, or otherwise
making Licensed Products available to third parties without sale or other dispositions, whether invoiced or not, less the following items: (a) returns, allowances, and credits given or made for rejection or return of previously sold
Licensed Products or Licensed Processes or for retroactive price reductions that are actually allowed and granted in the specific reporting period, (b) packing costs, insurance costs, freight out, and other transportation
charges, (c) taxes or excise duties or other governmental charges imposed on the transaction (if separately invoiced), (d) rebates and chargeback payments granted to managed health care organizations, pharmacy benefit managers (or equivalents
thereof), and (e) wholesaler and cash and quantity discounts in amounts customary in the trade to the extent actually granted. No deductions shall be made for [***]. 

Notwithstanding the foregoing, transfers of Licensed Product or practice of the Licensed Process internally among
Licensee, its Affiliate(s), or their respective sublicensees shall be exempt from the calculation of Net Sales, unless the recipient is an end user of the Licensed Product or Licensed Process. The supply of
Licensed Product or practice of Licensed Process as samples for charitable, or non-commercial purposes, for use in non-clinical or clinical trials, or any
test or other studies reasonably necessary to comply with any applicable laws shall not be included in the calculation of Net Sales. 
  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 6
 of 36     [Final]     [Icosavax, Inc.] 

	 	2.20	 “Phase I Clinical Trial” means a human clinical trial (including Phase Ia and Ib) in
any country that includes studies in humans of the safety and tolerability of, and information regarding pharmacokinetics and potential pharmacological activity of an investigational product that would satisfy the requirements of 21 CFR 312.21(a).

  

	 	2.21	 “Phase II Clinical Trial” means a human clinical trial (including Phase 2a and 2b) in any
country that includes studies in humans of the safety, dose ranging and efficacy of an investigational product that would satisfy the requirements of 21 CFR 312.21(b). 

 

	 	2.22	 “Phase III Clinical Trial” means a human clinical trial in any country that provides for
expanded study of a product on sufficient numbers of patients to establish the safety and efficacy of a product and generate, if required, pharmacological data to support regulatory approval in the proposed therapeutic indications that would satisfy
the requirements of 21 CFR 312.21(c). 

  

	 	2.23	 “Phase IV Clinical Trial” means a human clinical trial in any country occurring after
marketing approval for purposes of gathering information on a vaccine’s effect in various populations and any side effects associated with long-term use of the vaccine. 

 

	 	2.24	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

  

	 	2.25	 “Regulatory Authority” means any applicable government regulatory authority involved in
granting approvals for the manufacturing, marketing, reimbursement and/or pricing of Licensed Products in the Licensed Territory, including, in the United States, the United States Food and Drug Administration and any successor
governmental authority having substantially the same function. 

  

	 	2.26	 “Valid Claim” means a claim of an issued and unexpired patent that is in force included within
the Licensed Patent Rights which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction (which decision is not appealable or has not been appealed within the time
allowed for appeal), and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise. 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 7
 of 36     [Final]     [Icosavax, Inc.] 

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The NIAID hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, a nonexclusive license under the Licensed Patent Rights listed in Appendix A (I and II) and under the provided Licensed Additional Documentation in the Licensed Territory to make and have made, to use and have
used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use. For the sake of
clarity, Licensee shall have the right to transfer Licensed Products, Licensed Materials or Licensed Additional Documentation to the Licensee’s Affiliate(s), sublicensees, and third-party contractors to
conduct commercial research and/or product development using the Licensed Products or Licensed Materials solely in accordance with the terms of this Agreement, provided that such entities may not use the Licensed Products
or Licensed Materials for any purpose other than that described herein, and consent to be bound by any applicable terms and obligations of this Agreement. 

 

	 	3.2	 The NIAID grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, a nonexclusive license under the Licensed Patent Rights to make and have made, to use and have used, and to import and have imported the Licensed Materials listed in Appendix B in the Licensed Field of Use. For
the sake of clarity, Licensee has no right to sell and have sold, or to offer to sell, Licensed Materials. 

  

	 	3.3	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the NIAID other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	 	3.4	 The NIAID agrees to use reasonable efforts to transfer copies of the Licensed Additional
Documentation, as available, to Licensee promptly after the effective date of this Agreement. The NIAID acknowledges that information relating to the Licensed Patent Rights or Licensed Products may be of
assistance to the Licensee in its research efforts. Accordingly, the NIAID shall consider reasonable requests by the Licensee for access to the inventors of the Licensed Patent Rights, Licensed Additional
Documentation, and Licensed Materials. 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 8
 of 36     [Final]     [Icosavax, Inc.] 

	4.	 SUBLICENSING 

  

	 	4.1	 Upon [***], the Licensee may enter into sublicensing agreements under the Licensed Patent Rights
only when it concurrently licenses or has previously licensed other proprietary or in-licensed intellectual property rights.    For the avoidance of doubt, the Licensee does not have
the right to solely sublicense the Licensed Patent Rights. The Licensee does not have the right to sublicense the Licensed Materials listed in Appendix B but shall have the right to transfer the Licensed Materials to its
Affiliates, sublicensees and third-party contractors pursuant to Section 3.1. 

  

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the
NIAID of Paragraphs 5.1, 5.2, 8.1, 10.1, 10.2, 12.5, and 13.7-13.9 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement. The Licensee
further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the NIAID, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is [***] contingent upon acceptance by the sublicensee of
the remaining provisions of this Agreement. 

  

	 	4.4	 The Licensee agrees to forward to the NIAID a [***] copy of each fully executed sublicense
agreement postmarked within thirty (30) days of the execution of the agreement. To the extent permitted by law, the NIAID agrees to maintain each sublicense agreement in confidence. 

 

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

	 	5.1	 Prior to the First Commercial Sale, at the NIAID’s reasonable request and to the extent
available, the Licensee agrees to provide the NIAID with reasonable quantities of Licensed Products or materials made through the Licensed Processes not to exceed [***] per calendar year for the
NIAID’s internal, pre-clinical research use only. NIAID may not transfer any Licensed Products pursuant to this Paragraph 5.1 to any organization, entity, or
governmental agency other than NIAID without the prior written consent of Licensee. 

  

	 	5.2	 To the extent required under 35 U.S.C. §204, as amended, the Licensee agrees that products used or
sold in the United States embodying Licensed Products or produced through use of Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the NIAID.

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 9
 of 36     [Final]     [Icosavax, Inc.] 

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the NIAID a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the NIAID a minimum annual royalty as set forth in Appendix C.

  

	 	6.3	 The Licensee agrees to pay the NIAID earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the NIAID benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the NIAID sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the Licensed
Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses; or 

 

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

  

	 	6.7	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.8	 On sales of Licensed Products by the Licensee or its Affiliates or sublicensees on sales
made in other than an arms-length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arms-length transaction in the same country, based on sales of like quantity and quality products on or about the time of this transaction. 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 10
 of 36     [Final]     [Icosavax, Inc.] 

	 	6.9	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIAID prior to the effective date of this Agreement, the Licensee shall pay the NIAID, as an additional royalty, within
sixty (60) days of the NIAID’s submission of a statement and request for payment to the Licensee, an amount equivalent to [***] of said unreimbursed patent expenses previously paid by the NIAID. As of May 18,
2018, the total of such unreimbursed patent expenses equals approximately [***] US dollars. 

  

	 	6.10	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIAID on or after the effective date of this Agreement, the NIAID, at its sole option, may require the Licensee:

  

	 	(a)	 to pay the NIAID on an annual basis, within [***] of the NIAID’s submission of a statement
and request for payment, a royalty amount equivalent to [***] of the patent expenses paid by the NIAID during the previous calendar year(s) or in the event that there are more than [four (4)] licensees for that calendar year(s) with similar
obligations, then a proportional percentage of such expenses for that year, whatever is less; 

  

	 	(b)	 to pay these unreimbursed expenses directly to the law firm employed by the NIAID to handle these
functions. However, in this event, the NIAID and not the Licensee shall be the client of the law firm; or 

  

	 	(c)	 under exceptional circumstances, the Licensee may be given the right to assume responsibility for the
preparation, filing, prosecution, or maintenance of any patent application or patent included with the Licensed Patent Rights. In that event, the Licensee shall directly pay the attorneys or agents engaged to prepare, file, prosecute,
or maintain these patent applications or patents and shall provide the NIAID with copies of each invoice associated with these services as well as documentation that these invoices have been paid. 

 

	 	6.11	 The NIAID agrees, upon written request, to provide the Licensee with summaries of patent
prosecution invoices for which the NIAID has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the NIAID related to patent prosecution costs shall be
treated as confidential commercial information and shall not be released to a third party except as required by law or a court of competent jurisdiction. 

  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 11
 of 36     [Final]     [Icosavax, Inc.] 

	 	6.12	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon [***] written notice to the NIAID and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after the effective date of the written notice.

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 The NIAID agrees to take responsibility for the preparation, filing, prosecution, and maintenance of any
and all patent applications or patents included in the Licensed Patent Rights. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of Licensed Products made, used, sold,
or imported and Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the NIAID. These records shall be retained for at least [***] following a given reporting period and shall be
available during normal business hours for inspection, at the expense of the NIAID, by an accountant or other designated auditor selected by the NIAID and reasonably acceptable to Licensee for the sole purpose of verifying
reports and royalty payments hereunder. NIAID may conduct such inspection no more than once per calendar year and may inspect records from a particular reporting period only once. The accountant or auditor shall sign Licensee’s
standard confidentiality agreement prior to the inspection and shall only disclose to the NIAID information relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or
underpayment in excess of [***] for any twelve (12) month period, then the Licensee shall reimburse the NIAID for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional
royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within [***] of the date the NIAID provides the Licensee notice of the payment due. If an inspection shows an overpayment for any
twelve (12) month reporting period, Licensee shall be entitled to credit the amount of such overpayment against any future non-patent prosecution royalty amounts owed by Licensee under this
Agreement. 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 12
 of 36     [Final]     [Icosavax, Inc.] 

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the NIAID with the
Commercial Development Plan in Appendix E, under which the Licensee intends to develop the Licensed Products or Licensed Processes with an intent of achieving the Practical Application of the Licensed
Patent Rights. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

 

	 	9.2	 The Licensee shall provide written annual reports on its product development progress or efforts to
commercialize under the Commercial Development Plan for the Licensed Fields of Use within [***] after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and
development, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, [***]. The NIAID also encourages these reports to include
information on any of the Licensee’s public service activities that relate to the Licensed Patent Rights. If reported progress differs from that projected in the Commercial Development Plan and Benchmarks, the
Licensee shall explain the reasons for such differences. In any annual report, the Licensee may propose amendments to the Commercial Development Plan, acceptance of which by the NIAID may not be denied unreasonably. The
Licensee agrees to provide any additional information reasonably required by the NIAID to evaluate the Licensee’s performance under this Agreement. The Licensee may amend the Benchmarks at any time upon
written approval by the NIAID. The NIAID shall not unreasonably withhold condition, or delay approval of any request of the Licensee to extend the time periods of this schedule if the request is supported by a reasonable showing
by the Licensee of diligence in its performance under the Commercial Development Plan and toward bringing the Licensed Products to the point of Practical Application. 

 

	 	9.3	 The Licensee shall report to the NIAID the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within thirty (30) days of such occurrences. 

  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 13
 of 36     [Final]     [Icosavax, Inc.] 

	 	9.4	 The Licensee shall submit to the NIAID, within [***] after each calendar half-year ending June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of
the Licensed Products sold or Licensed Processes practiced by or on behalf of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty
report, the Licensee shall submit payment of earned royalties due. If no earned royalties are due to the NIAID for any reporting period, the written report shall so state. The royalty report shall [***] include a detailed listing of
all deductions made under Paragraph 2.18 to determine Net Sales made under Article 6 to determine royalties due. 

  

	 	9.5	 The Licensee agrees to forward semi-annually to the NIAID
a copy of these reports (and/or relevant portion thereof) received by the Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the
NIAID by the Licensee for activities under the sublicense. 

  

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due, and any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the NIAID at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay this tax and be responsible for all filings with appropriate agencies of foreign governments. 

  

	 	9.8	 Additional royalties may be assessed by the NIAID on any payment that is more than [***] overdue at the
rate of [***] per month. This [***] per month rate may be applied retroactively from the original due date until the date of receipt by the NIAID of the overdue payment and additional royalties. The payment of any additional royalties shall
not prevent the NIAID from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 14
 of 36     [Final]     [Icosavax, Inc.] 

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee and
the Assignment Notice provided by the Licensee under Section 14.7 shall, to the extent permitted by law, be treated by the NIAID as commercial and financial information obtained from a person and as privileged and confidential,
and any proposed disclosure of these records by the NIAID under the Freedom of Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 CFR §5.65(d). 

 

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include reasonable efforts to adhere to the Commercial Development Plan in Appendix E and to perform
the Benchmarks in Appendix D. The efforts of a sublicensee shall be considered the efforts of the Licensee. The NIAID also agrees to make reasonable efforts to provide the Licensee with the Licensed Additional
Documentation set forth in Paragraph 3.4 hereof. The Licensee agrees to retain control over the Licensed Materials and Licensed Additional Documentation and shall not distribute or release them to others without the prior
written consent of the NIAID, except for Affiliate(s), sublicensees, and third-party contractors acting on Licensee’s behalf, as provided in Paragraph 3. 

 

	 	10.2	 Upon receipt and verification of the royalties due under Paragraph 6.1, the NIAID agrees to provide the
Licensee, at the Licensee’s expense, with samples of the Licensed Materials as available and identified in Appendix B to the individual and address listed in Appendix H and, at reasonable cost to the Licensee, to
replace them in the event of their unintentional destruction. 

  

	 	10.3	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make Licensed Products and Licensed Processes reasonably accessible to the United States public. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale, to make commercially reasonable quantities
of Licensed Products or materials produced through the use of Licensed Processes available to patient assistance programs in the U.S., if applicable. 

 

	 	10.5	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion in the U.S., to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed
Products. 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 15
 of 36     [Final]     [Icosavax, Inc.] 

	 	10.6	 The Licensee agrees to supply, to the Technology Transfer and Intellectual Property Office,
NIAID, at the mailing address 5601 Fishers Lane, Suite 6D, Rockville, Maryland 20852-3804 U.S.A., with inert samples of the Licensed Products or Licensed Processes or their packaging for educational and display purposes only.

  

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 The NIAID and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may reasonably be expected to affect the validity, scope, or enforceability of the Licensed Patent Rights of which either Party becomes aware.

  

	 	11.2	 In the event that a declaratory judgment action alleging invalidity of any of the Licensed Patent Rights
shall be brought against the NIAID, the NIAID agrees to notify the Licensee that an action alleging invalidity has been brought. The NIAID does not represent that it shall commence legal action to defend against a
declaratory action alleging invalidity. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. Should the Government be made a party to any suit by motion or
any other action of the Licensee, the Licensee shall reimburse the Government for any costs, expenses, or fees, which the Government incurs as a result of the motion or other action. Upon the Licensee’s
payment of all costs incurred by the Government as a result of the Licensee’s joinder motion or other action, these actions by the Licensee shall not be considered a default in the performance of any material obligation
under this Agreement. 

  

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The NIAID offers no warranties other than it warrants that those statements specified in Article 1 are
true and correct. 

  

	 	12.2	 The NIAID does not warrant the validity of the Licensed Patent Rights and makes no
representations whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties.

  

	 	12.3	 THE NIAID MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS, LICENSED MATERIALS OR LICENSED ADDITIONAL DOCUMENTATION OR TANGIBLE MATERIALS RELATED THERETO. 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 16
 of 36     [Final]     [Icosavax, Inc.] 

	 	12.4	 The NIAID does not represent that it shall commence legal actions against third parties infringing the
Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the NIAID, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage resulting from third party claims or demands in connection with or arising
out of: 

  

	 	(a)	 the use by or on behalf of the Licensee, or its sublicensees, or their directors, employees, or
third-party contractors of any Licensed Patent Rights or Licensed Materials or Licensed Additional Documentation; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or
materials by the Licensee, or other products or processes developed by Licensee or its sublicensees in connection with or arising out of the Licensed Patent Rights or Licensed Additional Documentation,

 except in each case (a) and (b) to the extent arising out of the NIAID’s breach of this
Agreement or the negligence or willful misconduct of the NIAID or any its employees, students, fellows, agents, or consultants. 
  

	 	12.6	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.

 13.    TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.15 are not
fulfilled, and shall extend to the expiration of the last to expire of the Licensed Patent Rights unless sooner terminated as provided in this Article 13. 

 

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the NIAID may terminate this
Agreement by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act; provided, however, that if the Licensee disputes in good faith that it has defaulted in its performance
of any material obligation under this Agreement or that any such default has not been timely remedied, the NIAID and the Licensee shall negotiate promptly and in good faith to resolve such dispute [***]. 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 17
 of 36     [Final]     [Icosavax, Inc.] 

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify the NIAID in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement in any country or
territory by giving the NIAID sixty (60) days written notice to that effect. 

  

	 	13.5	 The NIAID shall specifically have the right to terminate or modify, at its option, this
Agreement, if the NIAID reasonably determines that the Licensee, its Affiliate(s), or sublicensees: 

  

	 	(a)	 is not executing the Commercial Development Plan submitted with its request for a license, as amended
pursuant to Paragraph 9.2, and the Licensee cannot otherwise demonstrate to the NIAID’s satisfaction that the Licensee has taken, or can be expected to take within a reasonable time, effective steps to achieve Practical
Application of the Licensed Products or Licensed Processes; 

  

	 	(b)	 has not achieved the Benchmarks in at least one of the indications identified in Appendix D as may be
modified under Paragraph 9.2; 

  

	 	(c)	 has willfully made a false statement of, or willfully omitted, a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

	 	(e)	 is not keeping at least one Licensed Product or Licensed Process reasonably available to the
public in the U.S. after commercial use commences; or 

  

	 	(f)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2, unless
waived. 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 18
 of 36     [Final]     [Icosavax, Inc.] 

	 	13.6	 In making the determination referenced in Paragraph 13.5, the NIAID shall take into account the normal
course of such commercial development and manufacturing programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or
modification of this Agreement under Paragraph 13.5, the NIAID shall give written notice to the Licensee providing the Licensee specific notice of, and a ninety (90) day opportunity to respond to, the NIAID’s
concerns as to the items referenced in 13.5(a)-13.5(f). If the Licensee fails to alleviate the NIAID’s concerns as to the items referenced in
13.5(a)-13.5(f) or fails to develop a corrective action plan and initiate corrective action pursuant to such plan to the NIAID’s reasonable satisfaction, the NIAID may terminate this
Agreement upon written notice to the Licensee; provided, however, that if the Licensee disputes in good faith the NIAID’s determination with respect to any item(s) referenced in
13.5(a)-13.5(f), the NIAID and the Licensee shall negotiate promptly and in good faith to resolve such dispute. 

 

	 	13.7	 The NIAID reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this
Agreement if it is determined that the action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
Licensee. 

  

	 	13.8	 Within thirty (30) days of receipt of written notice of the NIAID’s unilateral decision to
modify or terminate this Agreement, the Licensee may, consistent with the provisions of 37 CFR §404.11, appeal the decision by written submission to the designated NIAID official. The decision of the designated NIAID
official shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be available. 

 

	 	13.9	 Within ninety (90) days of expiration or termination of this Agreement under this Article 13, a
final report shall be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the minimum annual royalty), and those related to patent expense, due to the NIAID shall become immediately due
and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the NIAID pursuant to Paragraph 4.3. Unless otherwise specifically provided for under
this Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products provided by the NIAID or other NIAID-provided materials included within the Licensed
Patent Rights to the NIAID or provide the NIAID with written certification of the destruction thereof. The Licensee may not be granted additional NIAID licenses if the final reporting requirement is not fulfilled.

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 19
 of 36     [Final]     [Icosavax, Inc.] 

 14.    GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of the Government to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by the Government or excuse a similar subsequent
failure to perform any of these terms or conditions by the Licensee. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the Parties relating to the subject matter of
the Licensed Patent Rights, Licensed Additional Documentation, Licensed Products and Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and
completely expressed by this Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this
Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

  

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be given by prepaid, first
class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the Signature Page, or to any other address as may be designated in
writing by such other party. Agreement notices shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated
receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of
timely mailing. 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 20
 of 36     [Final]     [Icosavax, Inc.] 

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) without the prior written consent of the NIAID, except that Licensee may assign this Agreement without
such consent to Licensee’s Affiliate(s) or to the successor of that part of Licensee’s business to which this Agreement pertains, whether such successor’s interest results from merger, sale of stock, sale
of assets or otherwise. In the case of such assignment to an Affiliate or successor, Licensee shall provide written notice of the anticipated assignment to the email inbox or mailing address on the signature page below that is at least
fifteen (15) calendar days before the effective date of the assignment, with receipt confirmed (which may be by automated method in the case of email or by U.S. Postal Service or commercial carrier if such notice is provided in accordance with
Section 14.6) (“Assignment Notice”). In the event that Licensee does not provide such Assignment Notice prior to Licensee’s assignment, the NIAID reserves the right to terminate or modify, at its
option, this Agreement. NIAID will have a period of thirty (30) calendar days from the date that it receives written notice from the Licensee of a proposed assignment for which NIAID’s written consent is
required, to approve or reject the proposed assignment and such approval shall not be unreasonably withheld. The parties agree that the identity of the parties is material to the formation of this Agreement and that the obligations under this
Agreement are nondelegable. In the event that the NIAID consents to a proposed assignment as set forth above, the Licensee shall pay the NIAID, as an additional royalty, [***] as consideration received for any
assignment of this Agreement within sixty (60) days of the assignment. 

  

	 	14.8	 The Licensee agrees in its use of any
NIAID-supplied materials to comply with all applicable statutes, regulations, and guidelines, including the NIH and the HHS regulations and guidelines. The Licensee agrees
not to use the NIAID-supplied materials for research involving human subjects or clinical trials in the United States without complying with 21 CFR Part 50 and 45 CFR Part 46. The Licensee agrees not to use the NIAID-supplied
materials for research involving human subjects or clinical trials outside of the United States without notifying the NIAID, in writing, of the research or trials and complying with the applicable regulations of the appropriate national
control authorities. Written notification to the NIAID of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of the research or trials.

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 21
 of 36     [Final]     [Icosavax, Inc.] 

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological materials, and other commodities. The transfer of these items
may require a license from the appropriate agency of the Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of the agency. The NIAID neither
represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to mark the Licensed Products, or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All Licensed Products manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve the NIAID patent
rights in those countries. 

  

	 	14.11	 By entering into this Agreement, the NIAID does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
NIAID, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the NIAID, NIH, FDA or HHS or the Government or their
employees in any advertising, promotional, or sales literature without the prior written approval of the NIAID. 

  

	 	14.12	 The Parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement. The Licensee agrees first to appeal any unsettled claims or controversies to the designated NIAID official, or designee, whose decision shall be considered the final agency decision. Thereafter, the
Licensee may exercise any administrative or judicial remedies that may be available. 

  

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 CFR Part 404 shall not be immunized from the operation of state or Federal law by reason of the source of
the grant. 

  

	 	14.14	 Paragraphs 8.1, 9.7-9.9,
12.1-12.5, 13.8, 13.9, 14.5, 14.7, 14.12 and 14.14 of this Agreement shall survive termination of this Agreement. 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 22
 of 36     [Final]     [Icosavax, Inc.] 

	 	14.15	 The terms and conditions of this Agreement shall, at the NIAID’s sole option, be considered
by the NIAID to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is
executed by the Licensee and a fully executed original is received by the NIAID within sixty (60) days from the date of the NIAID signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 
  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 23
 of 36     [Final]     [Icosavax, Inc.] 

 NIH PATENT LICENSE AGREEMENT NONEXCLUSIVE - SUBLICENSABLE 

SIGNATURE PAGE 
 For the NIAID:

  

					
	 /s/ Michael R. Mowatt
	  	 06/27/2018
	  	
	Michael R. Mowatt, Ph.D.	  	Date	  	

 Director 
 Technology Transfer and
Intellectual Property Office 
 National Institute of Allergy and Infectious Diseases 

Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: LicenseNotices_Reports@mail.nih.gov 
 For the Licensee (Upon, information and belief, the undersigned
expressly certifies or affirms that the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 

by: 
  

					
	 /s/ Adam Simpson
	  	 06/8/2018
	  	
	Signature of Authorized Official	  	Date	  	

  

			
	 Adam Simpson
	  	
	Printed Name	  	
		
	 Chief Executive Officer
	  	
	Title	  	

 Official and Mailing Address for Agreement notices: 

					
		 	 Adam Simpson
	 	
		 	Name	 	
			
		 	 Chief Executive Officer
	 	
		 	Title	 	
			
		 	 Mailing Address
	 	

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 24
 of 36     [Final]     [Icosavax, Inc.] 

					
		 	 1 Union Square
	  	
		 	 600 University Street, Suite 2525
	  	
		 	 Seattle, WA 98101
	  	
		 	  
	  	

									
					
		 	Email Address:	 		 		  	[***].
					
		 	Phone:	 		 	  
	  	
					
		 	Fax:	 		 	  
	  	
		
	I.	 	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments)

  

					
		  	 Adam Simpson
	  	
		  	Name	  	
			
		  	 Chief Executive Officer
	  	
		  	Title	  	
			
		  	Mailing Address:	  	
		  	 1 Union Square
	  	
		  	 600 University Street, Suite 2525
	  	
		  	 Seattle, WA 98101
	  	
		  	  
	  	

							
				
		 	Email Address:	 		  	[***]
				
		 	Phone:	 	  
	  	
				
		 	Fax:	 	  
	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001
(criminal liability including fine(s) and/or imprisonment). 
  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 25
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX A – [***] 

[***] 
  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 26
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	 	I.	 Licensed Materials: 

[***] 
  

	 	II.	 Licensed Fields of Use: 

 

	 	(a)	 Adjuvanted or non-adjuvanted vaccines for the prevention, cure,
amelioration or treatment of respiratory syncytial virus (RSV) infection in humans, for administration alone or in combination with one or more other vaccines. For the sake of clarity, such RSV vaccines as set forth in the Licensed Patent
Rights are limited to those that combine Licensed Patent Rights with Licensee’s proprietary protein-based nanoparticle technology and specifically excludes nucleic acid-based vaccines.

  

	 	(b)	 The use of the Licensed Materials listed in Appendix B (I) is limited to internal research, quality
control and characterization of Licensed Products only. 

  

	 	III.	 Licensed Territory: 

 

	 	(a)	 Worldwide 

  

	 	IV.	 Least Developed Countries: 

Africa (34): Angola, Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, Democratic Republic of the Congo, Djibouti,
Equatorial Guinea, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Niger, Rwanda, São Tomé and Príncipe,
Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Togo, Uganda, United Republic of Tanzania, Zambia  

Asia (14): Afghanistan, Bangladesh, Bhutan, Cambodia, Kiribati, Lao People’s Democratic Republic, Myanmar, Nepal, Samoa, Solomon
Islands, Timor-Leste, Tuvalu, Vanuatu, Yemen 
 Latin America and the Caribbean (1): Haiti 

(Source: United Nations Office of the High Representative (UN-OHRLLS) as of October 23, 2013)

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 27
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX C – ROYALTIES 

Royalties: 
  

	 	I.	 The Licensee agrees to pay to the NIAID a noncreditable, nonrefundable license issue royalty in
the amount of [***] within sixty (60) days from the effective date of this Agreement. 

  

	 	II.	 The Licensee agrees to pay to the NIAID a nonrefundable minimum annual royalty as follows:

  

	 	(a)	 [***] minimum annual royalty payments for Years Two through [***] are due and payable within [***] after
January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year. For clarity, Year Two shall begin on January 1, 2019 and the first minimum annual royalty payment is due and payable within
[***] of January 1, 2019; 

  

	 	(b)	 [***] minimum annual royalty payments for Years [***] through [***] are due and payable within [***] after
January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year; 

  

	 	(c)	 [***] minimum annual royalty payments for every year after Year [***] until prior to First Commercial
Sale are due and payable within [***] after January 1 of each calendar year and shall be credited against any earned royalties due for sales made in that year; and 

 

	 	(d)	 [***] minimum annual royalty payments for every year after First Commercial Sale as long as Licensed
Patent Rights exist, and have not expired, been revoked, lapsed, or held unenforceable, are due and payable within [***] after January 1 of each calendar year and shall be credited against any earned royalties due for sales made in that
year. 

  

	 	III.	 The Licensee agrees to pay the NIAID the following earned royalties on Net Sales of each
Licensed Product throughout the Licensed Territory in each calendar year by or on behalf of Licensee, its Affiliate(s), or its sublicensees. 

 

	 	(a)	 When Valid Claims exist in countries of manufacture or sale and in which Licensee has not
exercised its rights to terminate this Agreement: 

  

	 	(1)	 [***] on Net Sales in Least Developed Countries. 

 
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 28
 of 36     [Final]     [Icosavax, Inc.] 

	 	(2)	 [***] for the portion of annual Net Sales of the Licensed Products sold in such countries outside
of the Least Developed Countries which are less than or equal to [***]. 

  

	 	(3)	 [***] for the portion of annual Net Sales of the Licensed Products sold in such countries outside
of the Least Developed Countries which are over [***] US dollars [***]. 

  

	 	(4)	 Upon the first time the aggregate Net Sales of all Licensed Products achieve the following
thresholds, the Licensee agrees to pay the following one-time Benchmark royalties: 

  

	 	a.	 [***] dollars [***] when the aggregate Net Sales of all Licensed Products reaches [***] dollars
[***]; 

  

	 	b.	 [***] dollars [***] when the aggregate Net Sales of all Licensed Products reaches [***] dollars
[***]; and 

  

	 	c.	 [***] dollars [***] when the aggregate Net Sales of all Licensed Products reaches [***] dollars
[***] . 

  

	 	IV.	 The Licensee agrees to pay the NIAID Benchmark royalties within [***] of
Licensee’s achieving each of the following Benchmarks: 

  

	 	(a)	 [***] dollars [***] upon dosing of first patient in first Phase I Clinical Trial for the first and
second indications in the Licensed Field of Use; 

  

	 	(b)	 [***] dollars [***] upon dosing of first patient in first Phase Ib or Phase II Clinical Trial for the
first indication in the Licensed Field of Use; 

  

	 	(c)	 [***] dollars [***] upon dosing of first patient in first Phase Ib or Phase II Clinical
Trial for the second indication in the Licensed Field of Use; 

  

	 	(d)	 [***] dollars [***] upon dosing of first patient in first Phase III Clinical Trial for the first
indication in the Licensed Field of Use; 

  

	 	(e)	 [***] dollars [***] upon dosing of first patient in first Phase III Clinical Trial for the second
indication in the Licensed Field of Use; 

  

	 	(f)	 [***] dollars [***] upon marketing approval received from a Regulatory Authority in the US or first
Major Market outside US for the first indication in the Licensed Field of Use; and 

  

	 	(g)	 [***] dollars [***] upon marketing approval received from a Regulatory Authority in the US or first
Major Market outside the US for the second 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 29
 of 36     [Final]     [Icosavax, Inc.] 

	 	
indication in the Licensed Field of Use. 

 The Benchmark
royalties shall be payable only upon the initial achievement of such Benchmark exercised in performance of the Licensed Field of Use and no amounts shall be due hereunder for subsequent or repeated achievement of such Benchmark.

  

	 	V.	 The Licensee agrees to pay the NIAID additional sublicensing royalties proportional to the fair
market value of any consideration received that is directly attributable to granting a sublicense to the Licensed Patent Rights. The payments shall be made within [***] of the execution of each sublicense and calculated as follows:

  

	 	(a)	 For sublicenses granted before [***] for any Licensed Product in the US or foreign equivalent:

  

	 	(1)	 [***] for the first indication in the Licensed Field of Use; and 

	 	(2)	 [***] for the second and each subsequent indication in the Licensed Field of Use; and

  

	 	(b)	 For sublicenses granted after the [***] for any Licensed Product but before the [***]for any Licensed
Product in the US or foreign equivalent: 

  

	 	(1)	 [***] for a first indication in the Licensed Field of Use; and 

	 	(2)	 [***] for the second and each subsequent indication in the Licensed Field of Use; and

  

	 	(c)	 For sublicenses granted after the [***] for any Licensed Product in the US or foreign equivalent:

  

	 	(1)	 [***] for a first indication in the Licensed Field of Use; and 

	 	(2)	 [***] for the second indication and each subsequent indication in the Licensed Field of Use.

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 30
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX D – BENCHMARKS AND PERFORMANCE 

The Licensee agrees to the following Benchmarks for its performance under this Agreement and, within thirty (30) days of achieving a
Benchmark, shall notify the NIAID that the Benchmark has been achieved. 
 Benchmarks for elderly vaccination indication 

 

	 	I.	 Submission of IND application to Regulatory Authority: Second (2nd) Quarter [***] 

  

	 	II.	 Dosing of first patient in Phase I Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	III.	 Dosing of first patient in Phase Ib or II Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	IV.	 Dosing of first patient in Phase III Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	V.	 Submission of BLA in the US or first Major Market outside US by a Regulatory Authority:
Third (3rd) Quarter [***] 

  

	 	VI.	 Marketing approval in the US or first Major Market outside US by a Regulatory Authority: Third (3rd) Quarter [***] 

 Benchmarks for maternal vaccination for prophylaxis in newborn
indication 
  

	 	VII.	 Submission of IND application to Regulatory Authority: Fourth (4th) Quarter [***] 

  

	 	VIII.	 Dosing of first patient in Phase I Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	IX.	 Dosing of first patient in Phase Ib or II Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	X.	 Dosing of first patient in Phase III Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	XI.	 Submission of BLA in the US or first Major Market outside US by a Regulatory Authority:
Third (3rd) Quarter [***] 

  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 31
 of 36     [Final]     [Icosavax, Inc.] 

	 	XII.	 Marketing approval in the US or first Major Market outside US by a Regulatory Authority: Third (3rd) Quarter [***] 

  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 32
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX E – COMMERCIAL DEVELOPMENT PLAN 

[***] 
  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 33
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX F – EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	 	•	 	 License reference number
(L-XXX-200X/0) 

  

	 	•	 	 Reporting period 

  

	 	•	 	 Catalog number and units sold of each Licensed Product (domestic and foreign) 

 

	 	•	 	 Gross Sales per catalog number per country 

 

	 	•	 	 Total Gross Sales 

  

	 	•	 	 Itemized deductions from Gross Sales 

 

	 	•	 	 Total Net Sales 

  

	 	•	 	 Earned Royalty Rate and associated calculations 

 

	 	•	 	 Gross Earned Royalty 

  

	 	•	 	 Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

 

	 	•	 	 Net Earned Royalty due 

Example 
  

													
	 Catalog Number
	 	Product Name	 	Country	 	Units Sold	 	 	Gross Sales
(US$)	 
	1	 	A	 	US	 	 	250	 	 	 	62,500	 
	1	 	A	 	UK	 	 	32	 	 	 	16,500	 
	1	 	A	 	France	 	 	25	 	 	 	15,625	 
	2	 	B	 	US	 	 	0	 	 	 	0	 
	3	 	C	 	US	 	 	57	 	 	 	57,125	 
	4	 	D	 	US	 	 	12	 	 	 	1,500	 
		 		 		 	 	        Total Gross Sales	 	 	 	153,250	 
		 		 		 	 	Less Deductions:	 	 			
		 		 		 	 	                Freight	 	 	 	3,000	 
		 		 		 	 	                Returns	 	 	 	7,000	 
		 		 		 	 	        Total Net Sales	 	 	 	143,250	 
		 		 		 	 	                Royalty Rate	 	 	 	8	% 
		 		 		 	 	                Royalty Due	 	 	 	11,460	 
		 		 		 	 	Less Creditable Payments	 	 	 	10,000	 
		 		 		 	 	        Net Royalty Due	 	 	 	1,460	 

  
 [***] 

CONFIDENTIAL 
 NIH Patent License Agreement
Nonexclusive - Sublicensable 
  Model 10-2015
                              Page
 34
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX G – ROYALTY PAYMENT OPTIONS 

[***] 
  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 35
 of 36     [Final]     [Icosavax, Inc.] 

 APPENDIX H – SHIPPING INFORMATION 

[***] 
  

[***] 
 CONFIDENTIAL 

NIH Patent License Agreement Nonexclusive - Sublicensable 

 Model 10-2015
                              Page
 36
 of 36     [Final]     [Icosavax, Inc.] 

 PUBLIC HEALTH SERVICE 

Amendment 
 This Agreement
is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for
Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

National Institute of Allergy and Infectious Diseases 

an Institute or Center (hereinafter referred to as the “NIAID”) of the 

NIH 
 and 

Icosavax, Inc., 
 hereinafter
referred to as the “Licensee”, 
 having offices at 1 Union Square, 600 University Street, Suite 2525, Seattle, Washington
98101, 
 created and operating under the laws of Delaware. 

Tax ID No.:            
[***]                         
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 1 of 7	  	

 FIRST AMENDMENT TO [***] 

This is the first amendment (“First Amendment”) of the agreement by and between the NIAID and Licensee having an
effective date of June 28, 2018 and having NIAID Reference Number [***] (“Agreement”). This First Amendment, having NIAID Reference Number [***] includes, in addition to the amendments made below, 1) a
Signature Page, 2) Attachment 1 (Shipping Information) and 3) Attachment 2 (Royalty Payment Information). 
 WHEREAS, the NIAID and the
Licensee desire that the Agreement be amended a first time as set forth below in order to update Appendix B to include additional Licensed Materials. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIAID and the Licensee, intending to be bound,
hereby mutually agree to the following: 
  

	1)	 Append Appendix B – I. Licensed Materials, to include as new item (f) [***] [***] protein.

  

	2)	 The Licensee shall pay the NIAID an amendment issue royalty in the sum of [***], which shall be
payable in installments as follows (payment options may be found in Attachment 2): 

  

	 	a.	 The first installment of [***] Dollars [***] payable within sixty (60) days from the effective date of
this First Amendment; and 

  

	 	b.	 The second installment of [***] Dollars [***] payable within sixty (60) days of the one (1) year
anniversary of the effective date of this First Amendment. 

  

	3)	 Upon receipt by NIAID of the first installment of the license amendment royalty and verification
thereof, NIAID agrees to provide the above-named Licensed Materials, as available, and to replace these Licensed Materials at reasonable cost, in the event of their unintentional destruction. 

 

	4)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1 and/or 2, such
provision(s) is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the shipping and payment information in such Attachment 1 and/or 2. 

 

	5)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	6)	 The terms and conditions of this First Amendment shall, at the NIAID’s sole option,
be considered by the NIAID to be withdrawn from the Licensee’s consideration and the terms and conditions of this First Amendment, and the First Amendment itself, to be null and void,
unless this First Amendment is executed by the Licensee and a fully executed original is received by the NIAID within sixty (60) days from the date of the NIAID’s signature found at the
Signature Page. 

  

	7)	 This First Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 2 of 7	  	

 FIRST AMENDMENT TO [***] 

SIGNATURE PAGE 
 In Witness Whereof, the
parties have executed this First Amendment on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below. 

For the NIAID: 
  

					
	 /s/ Michael R. Mowatt
	  	                	  	
08/30/2018                

	Michael R. Mowatt, Ph.D.	  		  	Date

 Director 
 Technology Transfer and
Intellectual Property Office 
 National Institute of Allergy and Infectious Diseases 

Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: LicenseNotices_Reports@mail.nih.gov 
 For the Licensee (Upon information and belief, the undersigned
expressly certifies or affirms that the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

					
	 /s/ Adam Simpson
	  	                	  	
09/10/2018                

	Signature of Authorized Official	  		  	Date

 Name: Adam Simpson 
 Title: Chief
Executive Officer 
  

	 	I.	 Official and Mailing Address for Agreement notices: 

 

			
	              	 	 Adam Simpson

		 	Name
		
		 	 Chief Executive Officer

		 	Title

  
 [***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 3 of 7	  	

 Mailing Address: 
  

					
	       
	 	 600 University Street, Suite 2525
	  	
			
		 	 Seattle, WA 98101
	  	
			
		 	  
	  	
			
		 	  
	  	

							
				
		 	Email Address:	  	adam.simpson@isosavax.com                                 
           	  	
				
		 	Phone:	  	  
	  	
				
		 	Fax:	  	  
	  	

  

	II.	 Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty
payments): 

  

					
	      	 	 Adam Simpson
	  	
		 	Name	  	
			
		 	 Chief Executive Officer
	  	
		 	Title	  	
			
		 	Mailing Address:	  	
			
		 	 600 University Street, Suite 2525
	  	
			
		 	 Seattle, WA 98101
	  	
			
		 	  
	  	
			
		 	  
	  	

							
				
		 	Email Address:	  	[***]                                   
                                         
        	  	
				
		 	Phone:	  	  
	  	
				
		 	Fax:	  	  
	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812
(civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 4 of 7	  	

 ATTACHMENT 1 – [***] 

 
 [***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 5 of 7	  	

 [***] 

[***] [***] [***] 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 6 of 7	  	

 ATTACHMENT 2 – [***] 

 

					
	[***]	  	[***]	  	[***]
	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]

  
 [***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	         Amendment of [***]	  	Icosavax, Inc.	  	
	Model 10-2015	  		  	
		  	Page 7 of 7	  	

 PUBLIC HEALTH SERVICE 

Amendment 
 This Agreement
is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for
Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

National Institute of Allergy and Infectious Diseases 

an Institute or Center (hereinafter referred to as the “NIAID”) of the 

NIH 
 and 

Icosavax, Inc, 
 hereinafter
referred to as the “Licensee”, 
 having offices at 1616 Eastlake Avenue East, Suite 208, Seattle, WA 98102, 

created and operating under the laws of Delaware. 

Tax ID No.: [***] 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 1 of 10	  	

 SECOND AMENDMENT TO [***] 

This is the Second amendment (“Second Amendment”) of the agreement by and between the NIAID and Licensee having an
effective date of June 28, 2018 and having NIAID Reference Number [***] (“Agreement”). This Second Amendment, having NIAID Reference Number [***] includes, in addition to the amendments made below, 1) a
Signature Page, 2) Attachment 1 (Shipping Information) and 3) Attachment 2 (Royalty Payment Information). 
 WHEREAS, the NIAID and the
Licensee desire that the Agreement be amended a second time as set forth below in order to add biological materials. 
  

	1.	 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIAID and
the Licensee, intending to be bound, hereby mutually agree to the following (all additions are shown in underline and deletions are shown in strike-out): 

 

	1)	 On page 1, amend Icosavax, Inc. address: 

Icosavax, Inc., hereinafter referred to as the “Licensee”, having offices at 1 Union Square, 600 University Street, Suite
2525, Seattle, Washington, 98101 1616 Eastlake Avenue East, Suite 208, Seattle, Washington, 98102, created and operating under the laws of Delaware. 
  

	2)	 On page 2, Add: 

For the NIAID’s internal use only: 

License Number: [***] 

License Application Number[***] 

Serial Number(s) of Licensed Patent(s) or Patent Application(s): 

 

	 	●	 	 [***] 

Public Benefit(s): Development of nanoparticle-based respiratory syncytial virus (“RSV”) and Meta Pneumovirus (hMPV)
vaccines 
  

	3)	 Add to Section 2 DEFINITIONS: 

2.27 “Third Party” means a person or entity other than (i) Licensee or any of its Affiliate(s) or
sublicensees and (ii) NIAID. 
  

	4)	 Add to Section 6.9: 

 
 [***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 2 of 10	  	

	 	6.9	 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the Licensed Patent Rights and paid by the NIAID prior to the effective date of this Agreement, the Licensee shall pay the NIAID, as an additional royalty, within
[***] of the NIAID’s submission of a statement and request for payment to the Licensee, an amount equivalent to [***] of said unreimbursed patent expenses previously paid by the NIAID. As of the effective date of this
Agreement, the total of such unreimbursed patent expenses equals approximately [***] US dollars. For any amendment to this License that includes additional Licensed Patent Rights, there will be an
additional royalty for the unreimbursed additional patent expenses. Licensee shall pay the NIAID the additional royalty within [***] of the NIAID’s submission of a statement and
request for payment to the Licensee, an amount equivalent to [***] of said unreimbursed additional patent expenses which is equivalent to [***]. 

 

	5)	 Addition to Appendix A: 

Patent(s) or Patent Application(s): 

[***] 
  

	6)	 Addition to Appendix B, Sections I and II: 

 

	 	I.	 Licensed Materials: 

[***] 

Licensed Fields of Use: 

Adjuvanted or non-adjuvanted vaccines for the prevention, cure, amelioration or treatment of disease caused by
metapneumovirus infection and/or respiratory syncytial virus (RSV) infection in humans, for administration alone or in combination with one or more other vaccines. For the sake of clarity, such vaccines as set forth in the
Licensed Patent Rights are limited to those that combine Licensed Patent Rights with Licensee’s proprietary technology and specifically excludes nucleic acid-based vaccines. 

The use of the Licensed Materials listed in Appendix B is limited to internal research, quality control and characterization of
Licensed Products only. 
  

	7)	 Appendix C - Roylaties 

In Appendix C, Royalties Section III, add Royalty add (4) d and (5): 

d. [***] dollars [***] when the aggregate Net Sales of all Licensed Products reaches [***] dollars [***]. 

(5) If the Licensee is required to pay royalties to one or more Third Parties in order to make and have made, use and have used,
sell and have sold, offer to sell, or import any License Products in the Licensed Field of Use, or to practice and have practiced any  
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 3 of 10	  	

 
Licensed Processes in the Licensed Field of Use (collectively “Third Party Royalties”), then the Licensee shall deduct [***] percent [***] for each [***] percent royalty due to a
Third Party up to a maximum of [***] percent [***] deduction from the royalty rate on Net Sales set forth under Paragraphs 6.3 of this Agreement. 

Delete Section IV in its entirety and replace with: 

The Licensee agrees to pay the NIAID Benchmark royalties within [***] of Licensee’s achieving each of the following Benchmarks:

 (a) [***] dollars [***] upon dosing of first patient in first Phase I Clinical Trial for the first and all subsequent indications in
the Licensed Field of Use; 
 (b) [***] dollars [***] upon dosing of first patient in first Phase II Clinical Trial for the first
indication in the Licensed Field of Use; 
 (c) [***] dollars [***] upon dosing of first patient in first Phase II Clinical Trial for
the second indication in the Licensed Field of Use; 
 (d) [***] dollars [***] upon dosing of first patient in first Phase II
Clinical Trial for the third indication in the Licensed Field of Use; 
 (e) [***] dollars [***] reupon dosing of first patient in
first Phase III Clinical Trial for the first indication in the Licensed Field of Use; 
 (f) [***] dollars [***] upon dosing of first
patient in first Phase III Clinical Trial for the second indication in the Licensed Field of Use; 
 (g) [***] thousand [***] upon
dosing of first patient in first Phase III Clinical Trial for the third indication in the Licensed Field of Use; 
 (h) [***] dollars
[***] upon marketing approval received from a Regulatory Authority in the US or first Major Market outside US for the first indication in the Licensed Field of Use; and 

(i) [***] dollars [***] upon marketing approval received from a Regulatory Authority in the US or first Major Market outside the US for the
second indication in the Licensed Field of Use. 
 (j) [***] dollars [***] upon marketing approval received from a Regulatory
Authority in the US or first Major Market outside the US for the third indication in the Licensed Field of Use. 
 The Benchmark
royalties shall be payable only upon the initial achievement of such Benchmark exercised in performance of the Licensed Field of Use and no amounts shall be due hereunder for subsequent or repeated achievement of such Benchmark. 

 

	8)	 Appendix D – Benchmarks and Performance 

Delete Appendix D in its entirety and replace with: 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 4 of 10	  	

 APPENDIX D – BENCHMARKS AND PERFORMANCE 

The Licensee agrees to the following Benchmarks for its performance under this Agreement and, within thirty (30) days of achieving
a Benchmark, shall notify the NIAID that the Benchmark has been achieved. 
 Benchmarks for elderly RSV vaccination
indication 
  

	 	I.	 Submission of IND or Foreign Equivalent application to Regulatory
Authority: Second (2nd) Quarter [***] 

  

	 	II.	 Dosing of first patient in Phase I Clinical Trial: Initiation by Fourth
(4th) Quarter [***]  

  

	 	III.	 Dosing of first patient in Phase Ib or II Clinical Trial:
Initiation by Fourth (4th) Quarter [***]  

  

	 	IV.	 Dosing of first patient in Phase III Clinical Trial: Initiation by Fourth
(4th) Quarter [***] 

  

	 	V.	 Submission of BLA or Foreign Equivalent in in the US or first Major
Market outside US to a Regulatory Authority: Third (3rd) Quarter [***] 

 

	 	VI.	 Marketing approval in the US or first Major Market outside US by a Regulatory
Authority: Third (3rd) Quarter [***] 

Benchmarks for maternal RSV vaccination for prophylaxis in newborn indication 

 

	 	I.	 Submission of IND or Foreign Equivalent application to
Regulatory Authority: Fourth (4th) Quarter [***] 

 

	 	II.	 Dosing of first patient in Phase I Clinical Trial: Initiation by Fourth
(4th) Quarter [***] 

  

	 	III.	 Dosing of first patient in Phase Ib or II Clinical Trial:
Initiation by Fourth (4th) Quarter [***] 

  

	 	IV.	 Dosing of first patient in Phase III Clinical Trial: Initiation by Fourth
(4th) Quarter [***] 

  

	 	V.	 Submission of BLA Foreign Equivalent in the US or first Major
Market outside US to a Regulatory Authority: Third (3rd) Quarter [***] 

 

	 	VI.	 Marketing approval in the US or first Major Market outside US by a Regulatory
Authority: Third (3rd) Quarter [***] 

Benchmarks for MPV vaccination (either in combination with RSV or alone) indication 

 

	 	I.	 Submission of IND or Foreing Equivalent application to Regulatory Authority: Fourth (4th) Quarter
[***] 

  

	 	II.	 Dosing of first patient in Phase I Clinical Trial: Initiation by Fourth (4th) Quarter [***] 

  

	 	III.	 Dosing of first patient in Phase Ib or II Clinical Trial: Initiation by Fourth (4th) Quarter [***]

  

	 	IV.	 Dosing of first patient in Phase III Clinical Trial: Initiation by Fourth (4th) Quarter [***]

  
 [***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 5 of 10	  	

 V. Submission of BLA or Foreign Equivalent in the US or first Major Market outside US to
a Regulatory Authority: Third (3rd) Quarter [***] 
 VI. Marketing approval in the US or first Major Market outside US by a
Regulatory Authority: Third (3rd) Quarter [***] 
 Appendix E – [***] 

 

	1)	 Within sixty (60) days of the execution of this Second Amendment, the Licensee shall
pay the NIAID an amendment issue royalty in the sum of [***] US Dollars [***] and payment options may be found in Attachment 2. 

  

	2)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1 and/or 2, such
provision(s) is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the shipping and payment information in such Attachment 1 and/or 2. 

 

	3)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	4)	 The terms and conditions of this Second Amendment shall, at the NIAID’s sole option, be
considered by the NIAID to be withdrawn from the Licensee’s consideration and the terms and conditions of this Second Amendment, and the Second Amendment itself, to be null and void,
unless this Second Amendment is executed by the Licensee and a fully executed original is received by the NIAID within sixty (60) days from the date of the NIAID’s signature found at the Signature
Page. 

  

	5)	 This Second Amendment is effective on upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 6 of 10	  	

 SECOND AMENDMENT TO [***] 

SIGNATURE PAGE 
 In Witness Whereof, the
parties have executed this Second Amendment on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below. 

For the IC: 
  

					
	 /s/ Michael R. Mowatt
	  	 8/20/2020
	  	
	Michael R. Mowatt, PhD.	  	Date	  	

 Director 
 Technology Transfer and
Intellectual Property Office, NIAID 
 National Institutes of Health 

Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: LicenseNotices_Reports@mail.nih.gov 
 For the Licensee (Upon information and belief, the undersigned
expressly certifies or affirms that the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

					
	 /s/ Adam Simpson
	  	 9/9/2020
	  	
	Signature of Authorized Official	  	Date	  	

  

			
	Name: Adam Simpson	  	
	Title: CEO, Icosavax, Inc.	  	

  

	 	

  

					
	        I.	  	Official and Mailing Address for Agreement notices:	 	
			
		  	 Cassia Cearley
	 	
		  	Name	 	
			
		  	 SVP, Operations
	 	
		  	Title	 	
			
		  	 Mailing Address:
	 	

  
 [***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 7 of 10	  	

					
		 	Icosavax, Inc.	  	
		 	 1616 Eastlake Ave. E., Suite 208
	  	
		 	 Seattle, WA 98116
	  	
		 	  
	  	

									
					
		 	Email Address:	  	[***]	  	  
	  	
					
		 	Phone:	  	[***]	  	  
	  	
				
		 	Fax:	  	  
	  	

  

							
	II.	 	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments):
				
		 	Accounts Payable	  		  	
		 	 c/o: Cassia Cearley
	  		  	
		 	Name	  		  	
				
		 	 SVP, Operations
	  		  	
		 	Title	  		  	
				
		 	Mailing Address:	  		  	
				
		 	 Icosavax, Inc.
	  		  	
		 	 1616 Eastlake Ave. E., Suite 208
	  		  	
		 	 Seattle, WA 98116
	  		  	
		 	  
	  		  	

									
					
		 	Email Address:	  	[***]	  	  
	  	
					
		 	Phone:	  	[***]	  	  
	  	
				
		 	Fax:	  	  
	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812
(civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 8 of 10	  	

 ATTACHMENT 1 – [***] 

[***] 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 9 of 10	  	

 ATTACHMENT 2 – [***] 

[***] 
  

[***] 

					
			
	CONFIDENTIAL -NIH	  		  	
	Second Amendment of [***]	  	Icosavax, Inc.	  	July 2020
	Model 10-2015	  	Page 10 of 10EX-10.15

 Exhibit 10.15 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 GRANT AGREEMENT 

Investment ID [***] 
 AGREEMENT
SUMMARY & SIGNATURE PAGE 
  

			
	 GRANTEE INFORMATION

	Name:	  	Icosavax, Inc.
	Tax Status:	  	 Not exempt from federal income tax under U.S. IRC § 501(c)(3)

You confirm that the above information is correct and agree to notify the Foundation immediately of any change.

	Expenditure Responsibility:	  	This Agreement is subject to “expenditure responsibility” requirements under the U.S. Internal Revenue Code.
	Mailing Address:	  	[***]
	Primary Contact:	  	Adam Simpson, [***]
	
	FOUNDATION INFORMATION
	Mailing Address:	  	[***]
	Primary Contact:	  	Harry Kleanthous, Senior Program Officer, Vaccine Discovery & Human Immunobiology, Global Health, [***]
	
	AGREEMENT INFORMATION
	Title:	  	IND prep and FIH Phase 1 study of SARS-CoV-2 RBD VLP vaccine
	“Charitable Purpose”:	  	To develop, manufacture and conduct clinical testing of a novel nanoparticle displaying a SARS-CoV2 vaccine co-administered with a novel adjuvant.
	“Start Date”:	  	Date of last signature
	“End Date”:	  	March 31, 2022
	This Agreement includes and incorporates by this reference:	  	 This Agreement Summary & Signature Page and:

•   Grant Amount and Reporting & Payment Schedule (Attachment A)

•   Terms and Conditions (Attachment B)

•   Investment Document (date submitted August 12, 2020)

•   Budget (date submitted July 16, 2020)

 THIS AGREEMENT is between Icosavax, Inc. (“You” or “Grantee”) and the Bill & Melinda Gates
Foundation (“Foundation”), and is effective as of the date of last signature. Each party to this Agreement may be referred to individually as a “Party” and together as the “Parties.” As a condition
of this grant, the Parties enter into this Agreement by having their authorized representatives sign below. 
  

									
	BILL & MELINDA GATES FOUNDATION	 		  	ICOSAVAX, INC.
			
	 /s/ Harry Kleanthous
	 		  	 /s/ Adam Simpson

	By:	 	Harry Kleanthous	 		  	By:	  	Adam Simpson
	Title:	 	SPO D&TS Vaccines & Human Immunobiology	 		  	Title:	  	Chief Executive Officer
			
	September 21, 2020	 		  	September 24, 2020
	Date	 		  	Date

  
 1 of 8 

 GRANT AGREEMENT 

Investment ID INV-[***] 

ATTACHMENT A 
 GRANT AMOUNT AND
REPORTING & PAYMENT 
 SCHEDULE 
 GRANT AMOUNT 

The Foundation will pay You the total grant amount specified in the Reporting & Payment Schedule below. The Foundation’s Primary Contact must approve in
writing any Budget cost category change of more than 10%. 
 REPORTING & PAYMENT SCHEDULE 

Payments are subject to Your compliance with this Agreement, including Your achievement, and the Foundation’s approval, of any applicable targets, milestones, and
reporting deliverables required under this Agreement. The Foundation may, in its reasonable discretion, modify payment dates or amounts and will notify You of any such changes in writing. 

REPORTING 
 You will submit reports according to the Reporting &
Payment Schedule using the Foundation’s templates or forms, which the Foundation will make available to You and which may be modified from time to time. For a progress or final report to be considered satisfactory, it must demonstrate
meaningful progress against the targets or milestones for that investment period. If meaningful progress has not been made, the report should explain why not and what adjustments You are making to get back on track. Please notify the
Foundation’s Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve any such changes in writing. You agree to submit other reports the Foundation may reasonably request. 

ACCOUNTING FOR PERSONNEL TIME 
 You will track the time of all employees,
contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds. Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty minutes or less and
brief descriptions of tasks performed. You will report actual time worked consistent with those records in Your progress and final budget reports. You will submit copies of such records to the Foundation upon request. 

 

									
	 REPORTING & PAYMENT SCHEDULE

					
	 Investment Period
	  	 Target, Milestone, or
Reporting Deliverable
	  	 Due By
	  	 Payment Date
	  	 Payment

Amount (U.S.$)

		  	Countersigned Agreement	  		  	Within 15 days after receipt of countersigned Agreement	  	$3,999,899.00
		  	Completion of Integrated Product Development Plan (IPDP) and Global Access Commitment Agreement (GACA)	  	December 1, 2020	  	December 2020	  	$2,700,000.00
	 Start Date to 
December 31, 2020
	  	ER Report	  	February 28, 2021	  	April 2021	  	$3,300,000.00
		  	Regulatory Submission	  	April 15, 2021
		  	Updated organizational financial statements
					
	 January 1, 2021 to December 31, 2021
	  	ER Report	  	February 28, 2022	  		  	
					
	 Start Date to End Date
	  	Final ER Report	  	May 31, 2022	  		  	
	Total Grant Amount	  	$9,999,899.00

  
 2 of 8 

 GRANT AGREEMENT 

Investment ID INV-[***] 

ATTACHMENT B 
 TERMS &
CONDITIONS 
 This Agreement is subject to the following terms and conditions. 

PROJECT SUPPORT     
 PROJECT DESCRIPTION AND
CHARITABLE PURPOSE 
 The Foundation is awarding You this grant to carry out the project described in the Investment Document (“Project”) in order
to further the Charitable Purpose. The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Investment Document. 

MANAGEMENT OF FUNDS     
 USE OF FUNDS 

You may not use funds provided under this Agreement (“Grant Funds”) for any purpose other than the Project. You may not use Grant Funds to reimburse any
expenses You incurred prior to the Start Date. At the Foundation’s request, You will repay any portion of Grant Funds and/or Income used or committed in material breach of this Agreement, as determined by the Foundation in its discretion. 

INVESTMENT OF FUNDS 
 You must invest Grant Funds in highly liquid investments
with the primary objective of preservation of principal (e.g., interest-bearing bank accounts or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under
this Agreement, You must report the amount of any currency conversion gains (or losses) and the amount of any interest or other income generated by the Grant Funds (collectively, “Income”). Any Income must be used for the Project.

 SEGREGATION OF FUNDS 
 You must maintain Grant Funds in a physically
separate bank account or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project. 
 GLOBAL
ACCESS     
 GLOBAL ACCESS COMMITMENT 
 You will
conduct and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments will survive the term of this Agreement. “Funded Developments” means the products, services,
processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). “Background
Technology” means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the Project used as part of the
Project. “Global Access” means: (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable
price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project. 

GLOBAL ACCESS MILESTONES 
 To further define Your Global Access commitments,
You are required to complete a Global Access Strategy and any other Global Access activities and documentation listed in the Reporting & Payment Schedule. The Global Access Strategy should address the following concepts with respect to all
Funded Developments: (a) identification of Background Technology at the outset of the Project and any Funded Developments created during the Project and specific strategies to ensure access to such Funded Developments and Background Technology;
(b) agreements and/or procedures for transfers of materials and data among Project Collaborators or third parties relevant to the Project; (c) reporting processes for the creation of Funded Developments to both the Project management team
and to the Foundation as well as the publishing and dissemination of the knowledge and information gained from the Project; (d) strategies to secure, manage and allocate intellectual property rights

  
 3 of 8 

 
associated with the Funded Developments or Background Technology in a way that ensures Global Access while providing incentives for future potential private sector participation; and
(e) anticipated development, commercialization and sustainability strategies during and after the Project to ensure that Global Access can be met. 
 You may not
materially change the plans and strategies contained in any Global Access documents after they have been approved by the Foundation without the Foundation’s prior written approval. You will provide the Foundation with updates to the Global
Access Strategy during each year of the Project describing any new or modified approaches with respect to Funded Developments and Background Technology, and related agreements, taking into account any new product, technology, and commercialization
developments and/or market information. “Global Access Strategy” means a written document, subject to the Foundation’s approval, describing how You intend to achieve Global Access given the particular circumstances of the
Project. “Project Collaborators” means all current and future subgrantees, subcontractors, partners, agents, affiliates, or other parties who provide any input to the Project. 

HUMANITARIAN LICENSE 
 Subject to applicable laws and for the purpose of
achieving Global Access, You grant the Foundation a nonexclusive, perpetual, irrevocable, worldwide, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, create derivative works, publicly
perform, and display Funded Developments and Essential Background Technology. “Essential Background Technology” means Background Technology that is: (a) owned, controlled, or developed by You, or
in-licensed with the right to sublicense; and (b) either incorporated into a Funded Development or reasonably required to exercise the license to a Funded Development. You confirm that You have retained
sufficient rights in the Funded Developments and Essential Background Technology to grant this license. You must ensure this license survives the assignment or transfer of Funded Developments or Essential Background Technology. On request, You must
promptly make available the Funded Developments and Essential Background Technology to the Foundation for use solely under this license. If You demonstrate to the satisfaction of the Foundation that Global Access can best be achieved without this
license, the Foundation and You will make good faith efforts to modify or terminate this license, as appropriate. 
 PUBLICATION 

Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the Foundation, You will seek
prompt Publication of any Funded Developments consisting of data and results. “Publication” means publication in a peer-reviewed journal or other method of public dissemination specified in the Project description or otherwise
approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers Global Access.
If You seek Publication in a peer-reviewed journal, such Publication shall be under “open access” terms and conditions consistent with the Foundation’s Open Access Policy available at: www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy, which may be modified from time to time. Nothing in this section shall be construed as requiring Publication in contravention of any
applicable ethical, legal, or regulatory requirements. You will mark any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (e.g., © 20<> <Name>). 

DATA ACCESS 
 The Foundation believes the requirement that the knowledge and
information gained from the Project be promptly and broadly disseminated extends to data and datasets generated through the Project. During the term of this Agreement, You will make cleaned datasets available to the Foundation upon request, at the
time they are generated, and for internal Foundation use only. Following the End Date, You will make all datasets available to the Foundation, upon request and for internal Foundation use only. From the date that is six (6) months after the End
Date, unless otherwise agreed with the Foundation, You will make all data generated under the Project available to the public in a manner and under conditions agreed to with the Foundation. 

INTELLECTUAL PROPERTY REPORTING 
 During the term of this Agreement and for 5
years after, You will submit upon request annual intellectual property reports relating to the Funded Developments, Background Technology, and any related agreements using the Foundation’s templates or forms, which the Foundation may modify
from time to time. 

  
 4 of 8 

 SUBGRANTS AND SUBCONTRACTS     

SUBGRANTS AND SUBCONTRACTS 
 You may not make subgrants under this Agreement.
You have the exclusive right to select subcontractors to assist with the Project. 
 RESPONSIBILITY FOR OTHERS 

You are responsible for (a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors, contingent workers, agents,
and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of this Agreement. 
 PROHIBITED
ACTIVITIES     
 ANTI-TERRORISM 
 You will not use
funds provided under this Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (www.treasury.gov/sdn) or
entities owned or controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine), including paying or
reimbursing the expenses of persons from such countries or territories, unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion. 

ANTI-CORRUPTION; ANTI-BRIBERY 
 You will not offer or provide money, gifts, or
any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Foundation or the Project, including by assisting any party to secure an improper advantage. Training and information on
compliance with these requirements are available at www.learnfoundationlaw.org. 
 POLITICAL ACTIVITY AND ADVOCACY 

You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not use Grant Funds to
support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local, state, federal, or
foreign lobbying law. You agree to comply with lobbying, gift, and ethics rules applicable to the Project. 
 OTHER     

PUBLICITY 
 A Party may publicly disclose information about the award of this
grant, including the other Party’s name, the total amount awarded, and a description of the Project, provided that a Party obtains prior written approval before using the other Party’s name for promotional purposes or logo for any purpose.
Any public disclosure by You or Your subgrantees, subcontractors, contingent workers, agents, or affiliates must be made in accordance with the Foundation’s then-current brand guidelines, which are available at:
www.gatesfoundation.org/brandguidelines. 
 LEGAL ENTITY AND AUTHORITY 
 You
confirm that: (a) You are an entity duly organized or formed, qualified to do business, and in good standing under the laws of the jurisdiction in which You are organized or formed; (b) You are not an individual (i.e., a natural person) or
a disregarded entity (e.g., a sole proprietor or sole-owner entity) under U.S. law; (c) You have the right to enter into and fully perform this Agreement; and (d) Your performance will not violate any agreement or obligation between You
and any third party. You will notify the Foundation immediately if any of this changes during the term of this Agreement. 
 COMPLIANCE WITH LAWS 

In carrying out the Project, You will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate the intellectual
property, privacy, or publicity rights of any third party. 

  
 5 of 8 

 COMPLIANCE WITH REQUIREMENTS 

You will conduct, control, manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable
international, national, local, and institutional standards (“Requirements”). You will obtain and maintain all necessary approvals, consents, and reviews before conducting the applicable activity. As a part of Your annual progress
report to the Foundation, You must report whether the Project activities were conducted in compliance with all Requirements. 
 If the Project involves: 

a. any protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the
Foundation without obtaining the Foundation’s prior written approval and all necessary consents to disclose such information; 
 b. children or vulnerable
subjects, You will obtain any necessary consents and approvals unique to these subjects; and/or 
 c. any trial involving human subjects, You will adhere to current
Good Clinical Practice as defined by the International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. 

Any activities by the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and complying with all
Requirements for the Project. 
 RELIANCE 
 You acknowledge that the
Foundation is relying on the information You provide in reports and during the course of any due diligence conducted prior to the Start Date and during the term of this Agreement. You represent that the Foundation may continue to rely on this
information and on any additional information You provide regarding activities, progress, and Funded Developments. 
 INDEMNIFICATION 

If the Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms, experimental
medicine, or the provision of medical/health services (“Indemnified Activities”), You will indemnify, defend, and hold harmless the Foundation and its trustees, employees, and agents (“Indemnified Parties”) from and
against any and all demands, claims, actions, suits, losses, damages (including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments, settlements, or costs or expenses (including reasonable
attorneys’ fees and expenses) (collectively, “Claims”) arising out of or relating to the acts or omissions, actual or alleged, of You or Your employees, subgrantees, subcontractors, contingent workers, agents, and affiliates
with respect to the Indemnified Activities. You agree that any activities by the Foundation in connection with the Project, such as its review or proposal of suggested modifications to the Project, will not modify or waive the Foundation’s
rights under this paragraph. An Indemnified Party may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are limited to the extent permitted or precluded under
applicable federal, state or local laws, including federal or state tort claims acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this Agreement will constitute an express or implied waiver
of Your governmental and sovereign immunities, if any. 
 INSURANCE 
 You
will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted industry standards and as required by law. You will ensure Your subgrantees and subcontractors
maintain insurance coverage consistent with this section. 
 TERM AND TERMINATION     

TERM 
 This Agreement commences on the Start Date and continues until the End
Date, unless terminated earlier as provided in this Agreement. The Foundation, in its discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and
adjusting any affected reporting requirements. 
 TERMINATION 
 The
Foundation may modify, suspend, or discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there are significant changes

  
 6 of 8 

 
to Your leadership or other factors that the Foundation reasonably believes may threaten the Project’s success; (c) there is a change in Your control; (d) there is a change in Your
tax status; or (e) You fail to comply with this Agreement. 
 RETURN OF FUNDS 

Any Grant Funds, plus any Income, that have not been used for, or committed to, the Project upon expiration or termination of this Agreement, must be returned promptly
to the Foundation. 
 MONITORING, REVIEW, AND AUDIT 
 The Foundation may
monitor and review Your use of the Grant Funds, performance of the Project, and compliance with this Agreement, which may include onsite visits to assess Your organization’s governance, management and operations, discuss Your program and
finances, and review relevant financial and other records and materials. In addition, the Foundation may conduct audits, including onsite audits, at any time during the term of this Agreement, and within four years after Grant Funds have been fully
spent. Any onsite visit or audit shall be conducted at the Foundation’s expense, following prior written notice, during normal business hours, and no more than once during any 12-month period. 

INTERNAL OR THIRD PARTY AUDIT 
 If during the term of this Agreement You are
audited by your internal audit department or by a third party, You will provide the audit report to the Foundation upon request, including the management letter and a detailed plan for remedying any deficiencies observed (“Remediation
Plan”). The Remediation Plan must include (a) details of actions You will take to correct any deficiencies observed, and (b) target dates for successful completion of the actions to correct the deficiencies. 

RECORD KEEPING 
 You will maintain complete and accurate accounting records
and copies of any reports submitted to the Foundation relating to the Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation’s request, You will make such records and reports
available to enable the Foundation to monitor and evaluate how Grant Funds have been used or committed. 
 SURVIVAL 

A Party’s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly provided in this Agreement or
otherwise required by law or intended by their nature. 
 GENERAL     

ENTIRE AGREEMENT, CONFLICTS, AND AMENDMENTS 
 This Agreement contains the
entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. If there is a conflict between this Agreement and the Investment Document this Agreement will prevail. Except as specifically
permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties. 

NOTICES AND APPROVALS 
 Written notices, requests, and approvals under this
Agreement must be delivered by mail or email to the other Party’s primary contact specified on the Agreement Summary & Signature Page, or as otherwise directed by the other Party. 

SEVERABILITY 
 Each provision of this Agreement must be interpreted in a way
that is enforceable under applicable law. If any provision is held unenforceable, the rest of the Agreement will remain in effect. 
 ASSIGNMENT 

You may not assign, or transfer by operation of law or court order, any of Your rights or obligations under this Agreement without the Foundation’s prior written
approval. This Agreement will bind and benefit any permitted successors and assigns. 

  
 7 of 8 

 COUNTERPARTS AND ELECTRONIC SIGNATURES 

Except as may be prohibited by applicable law or regulation, this Agreement and any amendment may be signed in counterparts, by facsimile, PDF, or other electronic
means, each of which will be deemed an original and all of which when taken together will constitute one agreement. Facsimile and electronic signatures will be binding for all purposes. 

  
 8 of 8 

							
	From:	 	                                [***]	  		  	
	Subject:	 	[***] AMD 1 to Icosavax, Inc.
	Date:	 	December 18, 2020 at 3:12 PM
		 	            [***]

  
  

Dear Adam, 
 Please review the amendment details below: 

 

			
	 AMENDMENT INFORMATION

	Agreement to be Amended:	  	Grant agreement between the Bill & Melinda Gates Foundation and Icosavax, Inc. effective September 24, 2020 and bearing Investment ID INV-[***]
	Amendment Purpose:	  	Updated Reporting & Payment Schedule
	Amendment Date:	  	Date of this email

 THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email.
Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict
between the Agreement and this Amendment, the terms of this Amendment will prevail. 
 UPDATED REPORTING & PAYMENT SCHEDULE 

This Amendment notifies you that the reporting and/or payment schedule for Your grant has changed. Your updated Reporting & Payment Schedule is deleted and
replaced with the following: 
  

									
	 REPORTING & PAYMENT SCHEDULE

					
	 Investment Period
	  	 Target, Milestone, or
Reporting Deliverable
	  	 Due By
	  	 Payment Date
	  	 Payment

Amount (U.S.$)

					
		  	Countersigned Agreement	  		  	PAID	  	$3,999,899.00
					
		  	Completion of Integrated Product Development Plan (IPDP) and Global Access Commitment Agreement (GACA)	  	January 31, 2021	  	February 2021	  	$2,700,000.00
	 Start Date to 
December 31, 2020
	  	ER Report	  	February 28, 2021	  	April 2021	  	$3,300,000.00
		  	Regulatory Submission	  	April 15, 2021
		  	Updated organizational financial statements
					
	 January 1, 2021 to December 31, 2021
	  	ER Report	  	February 28, 2022	  		  	
					
	 Start Date to End Date
	  	Final ER Report	  	May 31, 2022	  		  	
	Total Grant Amount	  	$9,999,899.00

 Please reply to this email to confirm your agreement to the above changes. 

Best, 
 Audra 

Audra Favini 

                [***] 

Bill & Melinda Gates Foundation 
 www.gatesfoundation.org 

IJ-Facebook 
 1:Twitter 

Il Impatient Optimists

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]